classification	minimum_mutations	mutations_per_mb	disease	context	oncotree_term	oncotree_code	therapy_name	therapy_strategy	therapy_type	therapy_sensitivity	therapy_resistance	favorable_prognosis	predictive_implication	description	preferred_assertion	source_type	citation	url	doi	pmid	nct	last_updated
High			Non-Small Cell Lung Cancer	Metastatic	Non-Small Cell Lung Cancer	NSCLC	Ipilimumab + Nivolumab	CTLA-4 inhibition + PD-1/PD-L1 inhibition	Immunotherapy	1			Guideline	"Nivolumab + ipilimumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB."		Guideline	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf				8/12/19
High			Non-Small Cell Lung Cancer	Metastatic	Non-Small Cell Lung Cancer	NSCLC	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	1			Guideline	"Nivolumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB."		Guideline	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf				8/12/19
High	178		Non-Small Cell Lung Cancer		Non-Small Cell Lung Cancer	NSCLC	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1			Clinical evidence	"In a validation set of 18 non-small cell lung cancer patients treated with pembrolizumab, a nonsynonymous mutational burden >= 178 was associated with durable clinical response in some patients (75% of patients with burden >= 178 showed a response, compared to 14% patients with burden < 178 that showed a response; sensitivity of 86%, specificity of 75%)."		Journal	"Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8."	https://doi.org/10.1126/science.aaa1348	10.1126/science.aaa1348	25765070		3/12/17
High	100		Melanoma	Metastatic	Melanoma	MEL	Ipilimumab	CTLA-4 inhibition	Immunotherapy	1			Clinical evidence	"In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment."		Journal	"Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99."	https://doi.org/10.1056/NEJMoa1406498	10.1056/NEJMoa1406498	25409260		3/12/17
High	100		Melanoma	Metastatic	Melanoma	MEL	Ipilimumab	CTLA-4 inhibition	Immunotherapy	1			Clinical evidence	A study of pretreatment biopsies of tumors from 110 patients showed that patients with a mutational load of >= 100 were significantly more likely to have a clinical benefit to ipilimumab.		Journal	"Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-11."	https://doi.org/10.1126/science.aad0095	10.1126/science.aad0095	26359337		3/12/17
High		10	Any solid tumor	Unresectable or metastatic	Any solid tumor		Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1			FDA-Approved	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."		FDA	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf				11/4/20